Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Psychiatry/Treatment Resistant Depression

Treatment Resistant Depression

21

Pipeline Programs↗

49

Active Trials↗

28

Companies Involved↗

Treatment Resistant Depression is an emerging landscape with 21 programs across 28 companies. The most active players are atai Therapeutics, Inc.. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

45/100

Mech. Concentration

27/100

Completion Rate

79/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

atai Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical15

Amitriptyline

AstraZeneca

Lamotrigine

Glaxo Dba Glaxosmithkline

Clomipramine

Specgx

Nortriptyline

Specgx

Paroxetine

Sebela Pharmaceuticals Development LLC

Phase 1

No programs

Phase 22

VLS-01-203 BU

atai Therapeutics, Inc.

BPL-003

Beckley Psytech Limited

Phase 34

Ketamine Hydrochloride

Boehringer Ingelheim

Psilocybin

COMPASS Pathways

NRX-101

NeuroRx, Inc.

Esketamine Hydrochloride

The Second Hospital of Anhui Medical University

Approved

No programs

Analysis

Trial Status

160

clinical trials

Completed77 · 48%

Recruiting34 · 21%

Terminated13 · 8%

Unknown status11 · 7%

Withdrawn8 · 5%

Active, not recruiting7 · 4%

Other10 · 6%

Clinical Trials

Trial Activity

160 trials

Lumateperone for Late-Life Depression

Recruiting·—·Phase 3·NCT07623135·100 enrolled

Characterizing Synaptic Density in Treatment Resistant Depression

Recruiting·UUnity Health Toronto·N/A·NCT03537794·45 enrolled

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

Recruiting·UUniversity of California, San Diego·Preclinical·NCT07217223·10 enrolled

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

Recruiting·NNorthwell Health·Phase 1·NCT06096207·20 enrolled

Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression

Recruiting·GGulhane Training and Research Hospital·Preclinical·NCT07673913·100 enrolled

Prefrontal Cortical Stimulation (PCS) for Severe Treatment Resistant Depression

Recruiting·UUniversity of Minnesota·Preclinical·NCT04124341·15 enrolled

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS

Recruiting·AAbbott Medical Devices·Preclinical·NCT06423430·100 enrolled

A Global PRospective, Multi-cEnter, ObServational Post-markeT Study tO Assess shoRt, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in reaL-world patIents With diFficult to Treat dEpression.

Recruiting·LLivaNova·N/A·NCT03320304·500 enrolled

The Copenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (CoMPACT) Trial

Recruiting·Danish Research Centre for Magnetic Resonance·Preclinical·NCT06895863·78 enrolled

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT07211438·40 enrolled

Higher, Faster, Better: Is an Accelerated Intermittent Theta Burst Stimulation Protocol Compared to Standard 10 Hz Repetitive Transcranial Magnetic Stimulation, More (Cost-) Effective in Patients With Treatment-resistant Depression?

Recruiting·AAmsterdam UMC, location VUmc·Preclinical·NCT05900271·108 enrolled

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (TREASURE Trial): a Pilot, Randomized Controlled Trial

Recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT06781697·31 enrolled

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06518720·16 enrolled

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06512220·12 enrolled

Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression

Recruiting·MMassachusetts General Hospital·Preclinical·NCT07563868·20 enrolled

Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)